Cardiovascular disease risk prediction among Iranian patients with diabetes mellitus in Isfahan Province, Iran, in ۲۰۱۴, by using Framingham risk score, atherosclerotic cardiovascular disease risk score, and high-sensitive C-reactive protein

سال انتشار: 1397
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 29

فایل این مقاله در 6 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

JR_RYA-14-4_004

تاریخ نمایه سازی: 2 شهریور 1401

چکیده مقاله:

BACKGROUND: Risk assessment in clinical practice plays an important role in classifying population for appropriate preventive medicine for each category. Several multivariable risk predictor algorithms and inflammatory biomarkers are developed for assessing risk for cardiovascular diseases (CVDs). We aimed to depict a picture of the cardiovascular risk profiles in the Iranian population with diabetes mellitus (DM) through three risk predictors for the first time, as the patients with DM have an increased risk for CVDs.METHODS: In this cross-sectional study, the sample size consisted of ۴۱۸ patients with DM from Diabetes Clinic of Shariati hospital, Isfahan, Iran, in February to July, ۲۰۱۴. We collected the latest information, and then calculated the ۱۰-year CVD risk using Framingham risk score (FRS) and atherosclerotic cardiovascular disease (ASCVD) risk score; while high-sensitivity C-reactive protein (hs-CRP) was measured for them based on their physicians' prescription. Finally, all data were analyzed using SPSS software.RESULTS: The mean ۱۰-year risk prediction of CVDs in the ۳۰- to ۷۴-year-old Iranian patients with DM was high in all three predictors based on their cut-off points, ۱۶.۳۱%, ۱۲.۳۹%, and ۳.۴۶ mg/l for FRS, ASCVD risk score, and hs-CRP level, respectively. Although the mean FRS and ASCVD risk scores were significantly higher among men than women (P < ۰.۰۵۰۰), the mean hs-CRP level was slightly lower in men than women (P > ۰.۰۵۰۰).CONCLUSION: Mean FRS and ASCVD risk scores and hs-CRP in patients were high, and a considerable proportion of patients with DM in our study were at intermediate and high risk for CVDs in the next ۱۰ years. Future cohort studies would investigate the accuracy of different predictors in upcoming years, and also help to derive a specific model or recalibrate existing predictors with characteristic of Iranian populations and specific target groups. 

نویسندگان

Nazanin Alaei Faradonbeh

General Practitioner, School of Medicine, Najafabad Branch, Islamic Azad University, Najafabad, Iran

Fariborz Nikaeen

Associate Professor, Department of Cardiology, School of Medicine, Najafabad Branch, Islamic Azad University, Najafabad, Iran

Mojtaba Akbari

Epidemiologist, Vice Chancellor for Research, Isfahan University of Medical Sciences, Isfahan, Iran

Naser Almasi

Medical Laboratory Scientist, Central Laboratory, Shariati Hospital, Isfahan, Iran

Mehrbod Vakhshoori

General Practitioner, Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

مراجع و منابع این مقاله:

لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :
  • World Health Organization. Global Status Report on Noncommunicable Diseases ۲۰۱۰. ...
  • Puska P, Norrving B, Mendis S. Global atlas on cardiovascular ...
  • Mathers CD, Loncar D. Projections of global mortality and burden ...
  • Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, ...
  • Chamnan P, Simmons RK, Sharp SJ, Griffin SJ, Wareham NJ. ...
  • Pfutzner A, Schondorf T, Hanefeld M, Forst T. High-sensitivity C-reactive ...
  • Ryden L, Grant PJ, Anker SD, Berne C, Cosentino F, ...
  • Chen SC, Su HM, Tsai YC, Huang JC, Chang JM, ...
  • Mora S, Yanek LR, Moy TF, Fallin MD, Becker LC, ...
  • Bosomworth NJ. Practical use of the Framingham risk score in ...
  • National Heart, Lung, and Blood Institute. Assessing cardiovascular risk: Systematic ...
  • Bisoendial RJ, Boekholdt SM, Vergeer M, Stroes ES, Kastelein JJ. ...
  • Hense HW, Schulte H, Lowel H, Assmann G, Keil U. ...
  • Jimenez-Corona A, Lopez-Ridaura R, Williams K, Gonzalez-Villalpando ME, Simon J, ...
  • Liu J, Hong Y, D'Agostino RB Sr, Wu Z, Wang ...
  • D'Agostino RB Sr, Grundy S, Sullivan LM, Wilson P. Validation ...
  • DeFilippis AP, Young R, McEvoy JW, Michos ED, Sandfort V, ...
  • Brindle P, Beswick A, Fahey T, Ebrahim S. Accuracy and ...
  • Bozorgmanesh M, Hadaegh F, Azizi F. Predictive accuracy of the ...
  • Khalili D, Hadaegh F, Soori H, Steyerberg EW, Bozorgmanesh M, ...
  • Chia YC, Lim HM, Ching SM. Validation of the pooled ...
  • Seo SM, Baek SH, Jeon HK, Kang SM, Kim DS, ...
  • Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, ...
  • Ford ES, Giles WH, Mokdad AH. The distribution of ۱۰-Year ...
  • Motamed N, Mardanshahi A, Saravi BM, Siamian H, Maadi M, ...
  • Khera A, McGuire DK, Murphy SA, Stanek HG, Das SR, ...